Faron Pharmaceuticals Oy

FARN

Company Profile

  • Business description

    Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in the regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is an anti-viral and anti-inflammatory agent, being tested for the prevention of complications that arise from cytokine release syndrome, or hyperinflammatory conditions.

  • Contact

    Joukahaisenkatu 6 B
    Turku20520
    FIN

    T: +358 24695151

    E: [email protected]

    https://www.faron.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    32

Stocks News & Analysis

stocks

Chart of the Week: Opportunities with wide-moat retailers

Consumer defensive names look undervalued.
stocks

New ASX share added to our best ideas

Earnings outlook is strong and the shares trade at a discount to our fair value.
stocks

Fair value downgraded for ASX heavyweight

Our capital allocation rating was also lowered due to balance sheet weakness.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,240.3042.600.46%
CAC 408,075.76108.811.37%
DAX 4024,449.08335.461.39%
Dow JONES (US)46,441.1043.210.09%
FTSE 1009,453.256.820.07%
HKSE27,287.12431.561.61%
NASDAQ22,755.1695.150.42%
Nikkei 22544,936.73385.880.87%
NZX 50 Index13,451.7617.770.13%
S&P 5006,711.2022.740.34%
S&P/ASX 2008,945.9040.100.45%
SSE Composite Index3,882.7820.250.52%

Market Movers